Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

Xiao Huang, Hai Lin, Feng Huang, Yuning Xie, Ka Hong Wong, Xiaoyu Chen, Dongyue Wu, Aiping LYU*, Zhijun YANG

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy, which is commonly associated with high incidence and mortality among adult patients. The standard induction regimen for AML has been substantially unchanged over the past 40 years, for which novel nanomedicines have represented a promising strategy in AML therapies. Despite developments of multiple nanoparticles formulated with drugs or genes, less there is not much information available about approaches in AML is available. This review presents an overview of nanomedicines currently being evaluated in AML. First, it briefly summarized conventional chemotherapies in use. Second, nanomedicines presently ongoing in clinical trials or preclinical researches were classified and described, with illustrative examples from recent literatures. Finally, limitations and potential safety issues concerns in clinical translation of AML treatment were discussed as well.

Original languageEnglish
JournalDose-Response
Volume17
Issue number4
DOIs
Publication statusPublished - 1 Oct 2019

Scopus Subject Areas

  • Toxicology
  • Public Health, Environmental and Occupational Health
  • Health, Toxicology and Mutagenesis
  • Chemical Health and Safety

User-Defined Keywords

  • acute myeloid leukemia
  • cancer therapy
  • nanomedicines
  • nanoparticles

Fingerprint

Dive into the research topics of 'Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this